Comparative Effects of Biofeedback-Enhanced Acapella vs. Standard Acapella on Pulmonary Function and Sputum Clearance in Moderate COPD

Background: Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and sputum retention. This study evaluated the efficacy of a Biofeedback-Enhanced Acapella device versus standard Acapella in moderate COPD patients (GOLD Stage II), with six mild COPD cases included due to recruitment challenges. Methods: A randomized, assessor-blinded experimental design enrolled 26 participants (14 Biofeedback-Enhanced, 12 Standard Acapella). Daily 20-minute sessions occurred for 5 days. Primary outcomes: FEV1, FVC, FEV1/FVC ratio, sputum weight. Secondary outcomes: Patient satisfaction (scores reported), vital signs (results included). Results: The Biofeedback-Enhanced group showed improvements in FEV1 (1.82L→2.25L, p=0.037), FVC (2.50L→3.00L, p=0.049), and sputum weight (20.1g→35.2g vs. 18.5g→27.8g, p=0.037). Patient satisfaction was higher (8.5±0.5 vs. 6.2±0.7, p=0.021). Vital signs improved: heart rate (80→78.78 bpm), respiratory rate (15.5→14.0 breaths/min), oxygen saturation (94.85%→95.78%). Conclusion: Biofeedback-Enhanced Acapella may improve pulmonary function and sputum clearance in moderate COPD over short-term use. Further long-term studies are warranted.